- Home
- MNPR vs TCI Comparison
MNPR vs TCI Comparison
Compare MNPR & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- TCI
- Stock Information
- Founded
- MNPR 2014
- TCI 1983
- Country
- MNPR United States
- TCI United States
- Employees
- MNPR N/A
- TCI N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- TCI Real Estate
- Sector
- MNPR Health Care
- TCI Finance
- Exchange
- MNPR Nasdaq
- TCI Nasdaq
- Market Cap
- MNPR 244.1M
- TCI 248.2M
- IPO Year
- MNPR 2019
- TCI N/A
- Fundamental
- Price
- MNPR $39.59
- TCI $28.23
- Analyst Decision
- MNPR Strong Buy
- TCI
- Analyst Count
- MNPR 5
- TCI 0
- Target Price
- MNPR $59.50
- TCI N/A
- AVG Volume (30 Days)
- MNPR 27.1K
- TCI 2.5K
- Earning Date
- MNPR 05-08-2025
- TCI 05-08-2025
- Dividend Yield
- MNPR N/A
- TCI N/A
- EPS Growth
- MNPR N/A
- TCI N/A
- EPS
- MNPR N/A
- TCI 0.68
- Revenue
- MNPR N/A
- TCI $47,778,000.00
- Revenue This Year
- MNPR N/A
- TCI N/A
- Revenue Next Year
- MNPR N/A
- TCI N/A
- P/E Ratio
- MNPR N/A
- TCI $41.60
- Revenue Growth
- MNPR N/A
- TCI N/A
- 52 Week Low
- MNPR $1.72
- TCI $25.50
- 52 Week High
- MNPR $54.30
- TCI $32.30
- Technical
- Relative Strength Index (RSI)
- MNPR 57.10
- TCI 49.21
- Support Level
- MNPR $26.06
- TCI $27.83
- Resistance Level
- MNPR $40.90
- TCI $28.80
- Average True Range (ATR)
- MNPR 4.78
- TCI 0.63
- MACD
- MNPR 0.64
- TCI -0.04
- Stochastic Oscillator
- MNPR 84.89
- TCI 23.48
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.